Healthcare & Life Sciences
Abzena Bio
United States
series-b
series-b
Stage
1
Investors
About
Develops antibody-drug conjugates (ADCs), which are engineered antibodies linked to cytotoxic agents, designed as targeted cancer therapeutics.
Explore Abzena Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.